The Role of the Distal Splenorenal Shunt in the Sclerotherapy Era?

1Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Between September 1982 and April 1988, 60 Cirrhotic patients with prior variceal hemorrhage were randomized to undergo the placement of an elective shunt (distal splenorenal: 26; nonselective: 4) or long-term endoscopic sclerotherapy (η = 30). Eighty- six percent of patients had alcoholic cirrhosis, and 33% were classified as Child’s class C. After a mean follow-up of 87 months, 60% of patients undergoing sclerotherapy and 17% of shunt patients experienced rebleeding (p < 0.001). Shunt patients have survived longer than those who had sclerotherapy (6-year survival rates of 53% and 26%, respectively; p <0.05). In part because of the wide geographic distribution of patients, only 4 of 13 patients in whom sclerotherapy failed (31%) could undergo salvage by shunt surgery. Although hepatic portal perfusion was better maintained after sclerotherapy, there were no major differences between the groups in terms of post-therapy hepatic or psychoneurologic function. In a predominantly alcoholic cirrhotic patient population (half non-urban), the results of elective shunt surgery were superior to those of chronic endoscopic sclerotherapy with respect to the prevention of recurrent variceal hemorrhage and survival. © 1994, Hindawi Publishing Corporation. All rights reserved.

Cite

CITATION STYLE

APA

Michael Henderson, J. (1994). The Role of the Distal Splenorenal Shunt in the Sclerotherapy Era? HPB Surgery, 8(1), 65–67. https://doi.org/10.1155/1994/37406

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free